[ Aadi Bioscience raises $23M in Series A ]

Aadi Bioscience has raised $23 million in Series A funding.

Founded by Dr. Neil Desai, Aadi Bioscience is a clinical-stage biopharmaceutical company that develops mTOR inhibitor for the treatment of oncology and cardiovascular diseases.

The company will use the capital to drive the clinical programs for ABI-009, its targeted albumin-bound mTOR inhibitor.

Funding  Series A
Founded  /
Country  USA
City  Pacific Palisades, California
Founder / CEO  Neil Desai
Deal Size  $23M
Investors  Star Summit Ventures
 Hermed Capital
 Celgene
 Vivo Capital
 Decheng Capital
 Helsinn Investment Fund
Previous Investors  /

[adyen action=”checkout_button”]